Exciting skincare to protect against blue light emitted by phones and devices
Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.
Allergan has launched the new SkinMedica LUMIVIVE System, an innovative skincare product designed with two distinct formulas - one to shield skin from blue light and environmental aggressors during the day and another to recharge the skin's essential repair process at night.
During the day, LUMIVIVE offers full atmospheric protection and fights the signs of ageing for optimal skin health and vitality. At night, LUMIVIVE supports the skin's ability to repair itself overnight, restoring the appearance of a glowing, youthful complexion. Unlike any other product on the market, the innovative LUMIVIVETM System formulas work around the clock to support optimal skin vitality and radiance, and doesn't fade throughout the day or wash off, providing 24-hour protection and revitalization.
"Skin today is under attack from multiple invisible threats," said San Diego-based dermatologist Dr Sabrina Fabi. "Visible light, including blue light like that emitted by phones and devices, is particularly insidious, because it penetrates deeper than some forms of ultraviolet light, down into the third layer of the skin, accelerating the visible signs of ageing, such as dark spots, wrinkles, and saggy or loose skin. I am excited to help launch this innovative product that not only repairs skin and promotes a healthy-looking complexion, but is potent enough to protect us from the many environmental elements that can leave skin looking less than its best."
In clinical studies, completed in some of the most polluted cities in the world, LUMIVIVE improved the appearance of skin tone, evenness and restored stressed skin for a more luminous complexion. 85% of patients agreed that LUMIVIVE reduced the effects of environmental damage on their skin and kept their skin looking radiant throughout the day.
"People around the world, spend an average of 2 hours per day on social media, while the average American looks at their phone 47 times a day and spends about 10 hours a day in front of a screen," says Carrie Strom, Senior Vice President, US Medical Aesthetics at Allergan. "We know that blue light and pollution are all around us and can't be avoided. We felt it was important to address an unmet need by creating a system that not only protects the skin from environmental damage during the day, but also enhances the skin's ability to restore and repair skin during the sleep-repair cycle as well."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance